Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Last Update: Sep 19, 2024

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

ClinicalTrials.gov Identifier:

NCT05156281

Novartis Reference Number:CLOU064C12302

See if you Pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS) The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.

The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).

The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.

A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.

Condition

Relapsing Multiple Sclerosis

Phase

Phase3

Overall Status

Recruiting

Number of Participants

800

Start Date

Dec 13, 2021

Completion Date

Oct 30, 2030

Gender

All

Age(s)

18 Years - 55 Years (Adult)

Interventions

Drug

Remibrutinib

tablet taken orally

Drug

Teriflunomide

capsule taken orally

Eligibility Criteria

Inclusion Criteria:

* 18 to 55 years of age
* Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
* At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
* EDSS score of 0 to 5.5 (inclusive)
* Neurologically stable within 1 month

Exclusion Criteria:

* Diagnosis of primary progressive multiple sclerosis (PPMS)
* Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
* History of clinically significant CNS disease other than MS
* Ongoing substance abuse (drug or alcohol)
* History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
* Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
* suicidal ideation or behavior
* Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
* Participants who have had a splenectomy
* Active clinically significant systemic bacterial, viral, parasitic or fungal infections
* Positive results for syphilis or tuberculosis testing
* Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
* Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
* Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
* History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.
* History of severe renal disease or creatinine level
* Participants at risk of developing or having reactivation of hepatitis
* Hematology parameters at screening:

* Hemoglobin: \< 10 g/dl (\<100g/L)
* Platelets: \< 100000/mm3 (\<100 x 109/L)
* Absolute lymphocyte count \< 800/mm3 (\<0.8 x 109/L)
* White blood cells: \<3 000/mm3 (\<3.0 x 109/L)
* Neutrophils: \< 1 500/mm3 (\<1.5 x 109/L)
* B-cell count \< 50% lower limit of normal (LLN) or total IgG \& total IgM \< LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
* History or current diagnosis of significant ECG abnormalities
* Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit
* Use of other investigational drugs
* Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
* History of gastrointestinal bleeding
* Major surgery within 8 weeks prior to screening
* History of hypersensitivity to any of the study drugs or excipients
* Pregnant or nursing (lactating) female participants, prior to randomization
* Women of childbearing potential not using highly effective contraception
* Sexually active males not agreeing to use condom
* Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
* Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply.

Novartis Investigative Site

Recruiting

Rosario,Santa Fe,S2000bzl,Argentina

Novartis Investigative Site

Recruiting

Rosario,Santa Fe,S2000dsw,Argentina

Novartis Investigative Site

Recruiting

San Miguel De,Tucuman,T4000,Argentina

Novartis Investigative Site

Recruiting

Buenos Aires,C1012aar,Argentina

Novartis Investigative Site

Recruiting

Caba,Buenos Aires,C1181ach,Argentina

Novartis Investigative Site

Recruiting

Bombal,Mendoza,M5500dxo,Argentina

Novartis Investigative Site

Recruiting

Porto Alegre,Rio Grande Do Sul,90035-001,Brazil

Novartis Investigative Site

Recruiting

Porto Alegre,RS,90110-000,Brazil

Novartis Investigative Site

Recruiting

Porto Alegre,RS,90430-001,Brazil

Novartis Investigative Site

Recruiting

Joinville,Santa Catarina,89202-165,Brazil

Novartis Investigative Site

Recruiting

Brasilia,DF,70200-730,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,01240-020,Brazil

Novartis Investigative Site

Recruiting

Vitoria,ES,29055-450,Brazil

Novartis Investigative Site

Recruiting

Curitiba,PR,81210-310,Brazil

Novartis Investigative Site

Recruiting

Sofia,1309,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1407,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1413,Bulgaria

Novartis Investigative Site

Recruiting

Plovdiv,4002,Bulgaria

Novartis Investigative Site

Recruiting

Ottawa,Ontario,K1h 8l6,Canada

Novartis Investigative Site

Recruiting

Levis,Quebec,G6w 0m5,Canada

Novartis Investigative Site

Recruiting

Montreal,Quebec,H4a 3t2,Canada

Novartis Investigative Site

Recruiting

St Jerome,Quebec,J7z 5t3,Canada

Novartis Investigative Site

Recruiting

Edmonton,Alberta,T6g 2b7,Canada

Novartis Investigative Site

Recruiting

Quebec,G1j 1z4,Canada

Novartis Investigative Site

Recruiting

Burnaby,British Columbia,V5g 2x6,Canada

Novartis Investigative Site

Recruiting

Halifax,Nova Scotia,B3h 4k4,Canada

Novartis Investigative Site

Recruiting

Wenzhou,Zhejiang,325000,China

Novartis Investigative Site

Recruiting

Wuhan,Hubei,430060,China

Novartis Investigative Site

Recruiting

Beijing,100034,China

Novartis Investigative Site

Recruiting

Nanjing,Jiangsu,210029,China

Novartis Investigative Site

Recruiting

Shanghai,200025,China

Novartis Investigative Site

Recruiting

Yinchuan,Ningxia,100039,China

Novartis Investigative Site

Recruiting

Shanghai,200040,China

Novartis Investigative Site

Recruiting

Taiyuan,Shanxi,030001,China

Novartis Investigative Site

Recruiting

Hangzhou,Zhejiang,310006,China

Novartis Investigative Site

Recruiting

Fuzhou,Fujian,350025,China

Novartis Investigative Site

Recruiting

Hangzhou,Zhejiang,310016,China

Novartis Investigative Site

Recruiting

Wuhan,Hubei,430030,China

Novartis Investigative Site

Recruiting

Zagreb,10000,Croatia

Novartis Investigative Site

Recruiting

Split,HRV,21000,Croatia

Novartis Investigative Site

Recruiting

Varazdin,HRV,42000,Croatia

Novartis Investigative Site

Recruiting

Vukovar,32000,Croatia

Novartis Investigative Site

Recruiting

Tallinn,11315,Estonia

Novartis Investigative Site

Recruiting

Tartu,50406,Estonia

Novartis Investigative Site

Recruiting

Lille,59037,France

Novartis Investigative Site

Recruiting

Clermont-Ferrand Cedex 1,63003,France

Novartis Investigative Site

Recruiting

Toulouse Cedex 9,31059,France

Novartis Investigative Site

Recruiting

Limoges,87042,France

Novartis Investigative Site

Recruiting

Contamine Sur Arve,74130,France

Novartis Investigative Site

Recruiting

Marseille,13003,France

Novartis Investigative Site

Recruiting

Dijon,21034,France

Novartis Investigative Site

Recruiting

Nice,06202,France

Novartis Investigative Site

Recruiting

Gonesse,95500,France

Novartis Investigative Site

Recruiting

Nantes,Cedex 1,44093,France

Novartis Investigative Site

Recruiting

Nimes,30029,France

Novartis Investigative Site

Recruiting

Grenoble,38042,France

Novartis Investigative Site

Recruiting

Toulon Cedex 9,Val De Marne,83800,France

Novartis Investigative Site

Recruiting

Poissy,78303,France

Novartis Investigative Site

Recruiting

Lille,59000,France

Novartis Investigative Site

Recruiting

Caen,14033,France

Novartis Investigative Site

Recruiting

Suresnes,92150,France

Novartis Investigative Site

Recruiting

Greece,53246,Greece

Novartis Investigative Site

Recruiting

Thessaloniki,Gr 54636,Greece

Novartis Investigative Site

Recruiting

Athens,Attica,11526,Greece

Novartis Investigative Site

Recruiting

Ioannina,GR,455 00,Greece

Novartis Investigative Site

Recruiting

Larissa,GR,411 10,Greece

Novartis Investigative Site

Recruiting

Athens,115 28,Greece

Novartis Investigative Site

Recruiting

Athens,12462,Greece

Novartis Investigative Site

Recruiting

Amritsar,Punjab,143006,India

Novartis Investigative Site

Recruiting

Hyderabad,Telangana,500082,India

Novartis Investigative Site

Recruiting

Lucknow,Uttar Pradesh,226007,India

Novartis Investigative Site

Recruiting

New Delhi,Delhi,110 060,India

Novartis Investigative Site

Recruiting

Kolkata,West Bengal,700017,India

Novartis Investigative Site

Recruiting

Kochi,Kerala,682025,India

Novartis Investigative Site

Recruiting

Pune,Maharashtra,411004,India

Novartis Investigative Site

Recruiting

Pune,Maharashtra,411013,India

Novartis Investigative Site

Recruiting

Napoli,80131,Italy

Novartis Investigative Site

Recruiting

Firenze,FI,50134,Italy

Novartis Investigative Site

Recruiting

Pozzilli,IS,86077,Italy

Novartis Investigative Site

Recruiting

Messina,ME,98121,Italy

Novartis Investigative Site

Recruiting

Modena,MO,41126,Italy

Novartis Investigative Site

Recruiting

Pavia,PV,27100,Italy

Novartis Investigative Site

Recruiting

Brindisi,BR,72100,Italy

Novartis Investigative Site

Recruiting

Orbassano,TO,10043,Italy

Novartis Investigative Site

Recruiting

Foggia,FG,71100,Italy

Novartis Investigative Site

Recruiting

Moriguchi,Osaka,570-8507,Japan

Novartis Investigative Site

Recruiting

Nishinomiya,Hyogo,663 8501,Japan

Novartis Investigative Site

Recruiting

Shinjuku-ku,Tokyo,160 8582,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,466 8560,Japan

Novartis Investigative Site

Recruiting

Suita,Osaka,565 0871,Japan

Novartis Investigative Site

Recruiting

Isehara,Kanagawa,259-1193,Japan

Novartis Investigative Site

Recruiting

Chiba,2608677,Japan

Novartis Investigative Site

Recruiting

Ichihara-city,Chiba,299-0111,Japan

Novartis Investigative Site

Recruiting

Higashimatsuyama,Saitama,355-0005,Japan

Novartis Investigative Site

Recruiting

Sagamihara,Kanagawa,252-0375,Japan

Novartis Investigative Site

Recruiting

Fukuoka,810-0022,Japan

Novartis Investigative Site

Recruiting

Fukuoka city,Fukuoka,812-8582,Japan

Novartis Investigative Site

Recruiting

Itabashi-ku,Tokyo,173-8610,Japan

Novartis Investigative Site

Recruiting

Kyoto-city,Kyoto,616-8255,Japan

Novartis Investigative Site

Recruiting

Niigata,951 8520,Japan

Novartis Investigative Site

Recruiting

Koriyama city,Fukushima,963-8052,Japan

Novartis Investigative Site

Recruiting

Kodaira,Tokyo,187-8551,Japan

Novartis Investigative Site

Recruiting

Sendai city,Miyagi,983 8512,Japan

Novartis Investigative Site

Recruiting

Sapporo city,Hokkaido,063-0005,Japan

Novartis Investigative Site

Recruiting

Shinjuku Ku,Tokyo,160-0023,Japan

Novartis Investigative Site

Recruiting

Kashihara city,Nara,634 8522,Japan

Novartis Investigative Site

Recruiting

Kobe-shi,Hyogo,650-0017,Japan

Novartis Investigative Site

Recruiting

Shinjuku ku,Tokyo,162 8666,Japan

Novartis Investigative Site

Recruiting

Ciudad De Mexico,14050,Mexico

Novartis Investigative Site

Recruiting

Queretaro,76070,Mexico

Novartis Investigative Site

Recruiting

Ciudad de Mexico,Distrito Federal,06700,Mexico

Novartis Investigative Site

Recruiting

Chihuahua,31203,Mexico

Novartis Investigative Site

Recruiting

Katowice,40-081,Poland

Novartis Investigative Site

Recruiting

Katowice,40-123,Poland

Novartis Investigative Site

Recruiting

Krakow,31-637,Poland

Novartis Investigative Site

Recruiting

Plewiska,Poznan,62-064,Poland

Novartis Investigative Site

Recruiting

Wroclaw,51-685,Poland

Novartis Investigative Site

Recruiting

Bialystok,15-704,Poland

Novartis Investigative Site

Recruiting

Zabrze,41-800,Poland

Novartis Investigative Site

Recruiting

Glogow,36-060,Poland

Novartis Investigative Site

Recruiting

Katowice,40 571,Poland

Novartis Investigative Site

Recruiting

Coimbra,3000 075,Portugal

Novartis Investigative Site

Recruiting

Leiria,2410-104,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1169 050,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1649 035,Portugal

Novartis Investigative Site

Recruiting

Matosinhos,Porto,4454509,Portugal

Novartis Investigative Site

Recruiting

Santa Maria da Feira,4520 211,Portugal

Novartis Investigative Site

Recruiting

Braga,4710243,Portugal

Caribbean Center for Clinical Research, Inc. .

Recruiting

Guaynabo,00968,Puerto Rico